TL;DR
Current data support the incorporation of tumor genomic analysis into routine clinical decision-making as an important step toward precision-based care in endometrial cancer, and suggest that molecular profiling may better identify patients who would benefit from treatment intensification or de-escalation compared with conventional risk assessment alone.
Background Stage II colon cancer is clinically heterogeneous. Current clinicopathologic risk factors cannot accurately identify patients with residual disease after curative resection. Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for the detection of minimal residual disease (MRD), defined as micr...
Current evidence suggests that NSMP tumors represent the most favorable subgroup for FST, showing the highest complete response rates and lowest recurrence rates, likely due to preserved estrogen and progesterone receptor signaling.
The postoperative management of resectable solid tumors depends on clinicopathological risk stratification. However, these static criteria often fail to identify occult minimal residual disease (MRD), resulting in suboptimal adjuvant treatment characterized by either overtreatment or undertreatment. Circulating tumor D...
Current professional guidance supports a cautious distinction between clinical validity and clinical utility: ctDNA can inform prognosis, counseling, and clinical-trial eligibility, but should not routinely replace standard surveillance or independently determine treatment escalation or de-escalation outside evidence-b...
Treatment delivered before surgery in colorectal cancer now encompasses several clinically distinct strategies rather than one uniform pathway. These include selective neoadjuvant chemotherapy for radiologically high-risk colon cancer, total neoadjuvant therapy (TNT) and response-adapted organ preservation in rectal ca...
Multibiomarker integration, supported by prospective validation and automated models, represents a promising approach to personalize treatment algorithms in early-stage TNBC, balancing efficacy and toxicity while guiding escalation and de-escalation strategies.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
